^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zepzelca (lurbinectedin)

    i
    Company:
    Boryung Group, Jazz, Key Oncologics, Luye Group, Merck (MSD), PharmaMar, Specialised Therap
    Drug class:
    Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor
    Related drugs:
    Apply
    Lurbinectedin in FET-Fused Tumors (LiFFT) (NCT05918640)
    Phase 1/2
    Children's Hospital of Philadelphia
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/27/2023
    Primary completion :
    07/30/2026
    Completion :
    07/30/2028
    EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4
    |
    Zepzelca (lurbinectedin)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (LURBIMUNE) (NCT05572476)
    Phase 2
    Institut Bergonié
    Withdrawn
    Last update posted :
    06/05/2024
    Initiation :
    10/01/2023
    Primary completion :
    05/31/2024
    Completion :
    05/31/2024
    PD-L1
    |
    carboplatin • Imfinzi (durvalumab) • etoposide IV • Zepzelca (lurbinectedin)
    Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (PM1183-A-014-15) (NCT02611024)
    Phase 1/2
    PharmaMar
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    05/06/2016
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    PD-L1
    |
    irinotecan • Zepzelca (lurbinectedin)
    Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer (NCT05800587)
    Phase 2
    Fox Chase Cancer Center
    Recruiting
    Last update posted :
    03/26/2024
    Initiation :
    02/22/2023
    Primary completion :
    08/01/2028
    Completion :
    08/01/2029
    CD4
    |
    carboplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • pemetrexed • etoposide IV • irinotecan • topotecan • Zepzelca (lurbinectedin)
    Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (NCT05126433)
    Phase 2
    Jazz Pharmaceuticals
    Completed
    Last update posted :
    02/26/2024
    Initiation :
    03/03/2022
    Primary completion :
    12/20/2023
    Completion :
    12/20/2023
    HER-2 • HRD
    |
    HER-2 negative
    |
    Zepzelca (lurbinectedin)
    Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations (NCT05229588)
    Phase 2
    HonorHealth Research Institute
    Recruiting
    Last update posted :
    02/02/2024
    Initiation :
    06/14/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2026
    BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY
    |
    BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation
    |
    Zepzelca (lurbinectedin)
    Study of Trilaciclib and Lurbinectidin (NCT05578326)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    11/16/2023
    Initiation :
    10/12/2022
    Primary completion :
    07/25/2024
    Completion :
    07/25/2026
    PD-L1
    |
    Zepzelca (lurbinectedin) • Cosela (trilaciclib)
    Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer (NCT04607954)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    07/24/2023
    Initiation :
    12/04/2020
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    PD-L1
    |
    Imfinzi (durvalumab) • topotecan • Zepzelca (lurbinectedin)
    Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors (NCT02454972)
    Phase 2
    PharmaMar
    Completed
    Last update posted :
    03/02/2023
    Initiation :
    08/25/2015
    Primary completion :
    09/18/2020
    Completion :
    09/18/2020
    BRCA1 • BRCA2 • BRCA
    |
    Zepzelca (lurbinectedin)
    Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma (NCT05042934)
    Phase 1b/2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    02/10/2022
    Initiation :
    09/15/2021
    Primary completion :
    08/30/2022
    Completion :
    08/30/2022
    EWSR1 • FLI1 • WRN • RECQL
    |
    irinotecan • Zepzelca (lurbinectedin)
    A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer (NCT01525589)
    Phase 2
    PharmaMar
    Completed
    Last update posted :
    09/25/2020
    Initiation :
    06/13/2012
    Primary completion :
    10/01/2018
    Completion :
    10/01/2018
    HER-2 • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 overexpression
    |
    Zepzelca (lurbinectedin)
    Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL) (NCT02421588)
    Phase 3
    PharmaMar
    Completed
    Last update posted :
    04/03/2020
    Initiation :
    05/01/2015
    Primary completion :
    10/12/2018
    Completion :
    10/12/2018
    MUC16
    |
    pegylated liposomal doxorubicin • topotecan • Zepzelca (lurbinectedin)
    Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors (POLA) (NCT02684318)
    Phase 1/2
    Poveda, Andrés, M.D.
    Unknown status
    Last update posted :
    06/22/2017
    Initiation :
    07/01/2015
    Primary completion :
    07/01/2019
    Completion :
    10/01/2019
    BRCA1 • PTEN • PARP1
    |
    BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation
    |
    Lynparza (olaparib) • Zepzelca (lurbinectedin)
    Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (NCT01314599)
    Phase 1
    PharmaMar
    Completed
    Last update posted :
    11/05/2015
    Initiation :
    05/01/2011
    Primary completion :
    07/01/2015
    Completion :
    07/01/2015
    ABL1 • BCR
    |
    Zepzelca (lurbinectedin)